Abstract
Acute nutrient deprivation (fasting) causes an immediate increase in spermidine biosynthesis in yeast, flies, mice and humans, as corroborated in four independent clinical studies. This fasting-induced surge in spermidine constitutes the critical first step of a phylogenetically conserved biochemical cascade that leads to spermidine-dependent hypusination of EIF5A (eukaryotic translation initiation factor 5A), which favors the translation of the pro-macroautophagic/autophagic TFEB (transcription factor EB), and hence an increase in autophagic flux. We observed that genetic or pharmacological inhibition of the spermidine increase by inhibition of ODC1 (ornithine decarboxylase 1) prevents the pro-autophagic and antiaging effects of fasting in yeast, nematodes, flies and mice. Moreover, knockout or knockdown of the enzymes required for EIF5A hypusination abolish fasting-mediated autophagy enhancement and longevity extension in these organisms. Of note, autophagy and longevity induced by rapamycin obey the same rule, meaning that they are tied to an increase in spermidine synthesis. These findings indicate that spermidine is not only a "caloric restriction mimetic" in the sense that its supplementation mimics the beneficial effects of nutrient deprivation on organismal health but that it is also an obligatory downstream effector of the antiaging effects of fasting and rapamycin.Abbreviation: EIF5A: eukaryotic translation initiation factor 5A; IGF1: insulin like growth factor 1; MTOR: mechanistic target of rapamycin kinase; ODC1: ornithine decarboxylase 1; TFEB: transcription factor EB.
Keywords:
Aging; MTOR; autophagy; lifespan; rapamycin; spermidine.
MeSH terms
-
Animals
-
Autophagy* / drug effects
-
Autophagy* / physiology
-
Caenorhabditis elegans / drug effects
-
Caenorhabditis elegans / metabolism
-
Eukaryotic Translation Initiation Factor 5A
-
Fasting
-
Humans
-
Longevity* / drug effects
-
Longevity* / physiology
-
Mice
-
Ornithine Decarboxylase / metabolism
-
Peptide Initiation Factors / metabolism
-
Sirolimus* / pharmacology
-
Spermidine* / metabolism
-
Spermidine* / pharmacology
Substances
-
Spermidine
-
Sirolimus
-
Eukaryotic Translation Initiation Factor 5A
-
Peptide Initiation Factors
-
Ornithine Decarboxylase
Grants and funding
This research was funded in whole, or in part, by the Austrian Science Fund (FWF) [10.55776/P37278, 10.55776/P37016, 10.55776/P31727, 10.55776/W1226]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. SJH is grateful for support from the Styrian Government for the grant “AutoKomm.” SS and MA acknowledge funding received from the Medical University of Graz (Flagship Project VASC-HEALTH). MA and GK acknowledge funding received from the FWF (DOI: 10.55776/I6931) and ANR under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme). MA acknowledges additional support from the FWF (DOI: 10.55776/P34926), and BioTechMed-Graz (Young Researcher Group). SS acknowledges the support from FWF through grants P27637-B28 and I3301, BioTechMed-Graz (Flagship project INTERACD+), and Medical University of Graz (Flagship project VASC-HEALTH). NT acknowledges support from the European Research Council (grant ERC-GA695190-MANNA), the European Commission (FETOPEN project Dynamic-GA‐863203, and Research Excellence Hub CHAngeing-GA‐101087071), the Greek National Research Infrastructure project BIOIMAGING‐GR-MIS5002755, the Hellenic Foundation for Research and Innovation and the General Secretariat for Research and Innovation.GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Joint Programme on Rare Diseases (EJPRD) Wilsonmed; European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444; project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue); The ERA4 Health Cardinoff Grant Ener-LIGHT; European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures [GOMS] associated with cancer incidence, prognosis and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878 : Project Acronym: Neutrocure; project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation); National support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen); Hevolution Network on Senescence in Aging (reference HF-E Einstein Network); Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology ANR-18-IDEX-0001; a Cancer Research ASPIRE Award from the Mark Foundation; PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030); Seerave Foundation; SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001. FM is grateful for support from the University of Graz for the grant “Fast4Health,” the Austrian Science Fund (FWF) for the grants P 37278-B, P 37016-B, P 31727-B21, W 1226, as well as BioTechMed-Graz (Flagship project EPIAge) and the University of Graz Field of Excellence BioHealth.